Moderna

Jim Cooper

Biopharma has been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). They’ve laid the necessary groundwork for cross-functional visibility, collaboration, and connectivity. 

With new entrants challenging the status quo, medicine has seen innovation at a pace unlike any other in generations. A constant quest for efficiencies and cost reductions is also a top priority for business professionals.

While economic pressures and engagement pressures loom, incumbents are under the constraint to be agile and adaptive. Identifying the relevance of innovations to solving business problems and capturing new opportunities for healthcare and life science leaders requires insights into their maturity and adoption.

Clinical, medical, and sales interactions between HCPs and organizations are rarely witnessed holistically by organizations, nor do they bear a comprehensive picture of their clients. However, the traditional distinctions between research, patient care, and thought leadership are becoming less distinct as a result of rare diseases with tiny patient populations and complex therapies. When these silos fall apart, biopharma can drive a more coordinated approach to HCP engagement using shared data and systems while retaining compliance.

For instance, seamless data sharing between clinical teams and medical scientific liaisons could substantially impact the choice of trial sites and guarantee better-coordinated collaboration. Leading businesses can provide their teams with the leeway to act promptly, legally, and with a shared understanding of the HCP.

Building trusted relationships and engaging clients on their terms with the ideal blend of in-person and digital techniques is imperative as access to HCPs rises from the pandemic's historic lows. The use of video as an additional channel to in-person advertising can boost reaction to promotions three times above in-person advertising alone. This will necessitate a change in how businesses view incentive compensation.

Incentives pay models will be directly impacted by omnichannel practices in 2023 due to the correlation between successful engagement data and sales results. Businesses will start to jettison conventional sales target approaches in favour of a hybrid model that rewards the proper rep actions that promote HCP engagement.

As a lagging indicator, traditional sales reporting will continue to play a significant role in the incentive compensation approach. Leading signs will include dependable, quantifiable omnichannel behaviours, such as the usage of video to support in-person engagement. By using this hybrid model, businesses will be able to identify performance gaps sooner and, for the first time, coordinate incentives throughout the commercial ecosystem, including sales representatives, key account managers, and medical science liaisons.

Pharma marketers must immediately react to generate, edit, and adjust the material to suit the needs of HCPs, who must get a constant supply of it. Although artificial intelligence (AI) has frequently been a useful tool and will continue to do so, automation will be the ultimate content accelerator in 2023. The benefits of automation are that businesses can operate more quickly without requiring large amounts of data as it does not pose the same risks as artificial intelligence. Numerous businesses already use automation with modular content to produce content more quickly, review and approve it more quickly, and reuse it across channels. Additionally, technologies like content creation tools, medical, legal, regulatory review (MLR), and digital asset management (DAM) will contribute to further acceleration.

Leading life sciences firms have realized that the human touch still plays a crucial and complementary role in the MLR process. Nevertheless, enterprises must maintain an appropriate mix of automation and subject-matter expertise brought by MLR professionals to ensure compliance.

In a year, biopharma will have the plan and tools to gather patient feedback and promptly take action on them. Companies will shorten trial periods and enhance launch trajectories with improved access to on-demand, precise, timely data that is integrated in a privacy-safe manner. Brands will be able to optimise and course-correct as needed by knowing how they are performing in the market. A better understanding of patients, additionally, will help companies plan their activations and interactions with HCPs.